In addition, the SINDAS trial in China revealed that patients with synchronous oligometastatic NSCLC and EGFR mutations who receive EGFR‐TKIs combined with radiotherapy (thoracic or metastasis radiotherapy) can achieve a longer OS than those who only receive EGFR‐TKIs (mOS: 25.5 vs. 17.4 months; p < 0.01).20 This evidence concerns the gene EGFR and non-small cell lung carcinoma.